Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Key Stats

Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Movers From Yesterday
Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Hikma Pharmaceuticals PLC ADR (HKMPY)
Ionis Pharmaceuticals
See More Headlines

OPNT Stock Analysis - Frequently Asked Questions

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
11/11/2021
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:OPNT) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners